Therefore, considering the potential permissive role of high GH/IGF1 levels, estrogen therapy might contribute to decreasing the risk of cancer development not only in conditions like acromegaly, characterized by an important excess of serum IGF1, but also in other tumors, whose development is linked to normal-high levels of GH/IGF1. The gene discussed is GH1; the disease is acromegaly.